Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML 2001
NCT01015196Phase 3Completed
- Sponsor
- CHU de Nantes
- Start
- Jan 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of daunorubicin in acute myeloid leukemia (AML), sponsored by CHU de Nantes. Started Jan 2001; status: completed.
02
Drugs
daunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01015196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01015196.